David R. Shprecher

David R. Shprecher, DO, MSCI, FAAN

Languages spoken: Spanish, English, Japanese

Academic Information

Departments Adjunct - Neurology

Board Certification

  • American Board of Psychiatry & Neurology (Neurology)

David Shprecher, DO Msci has dedicated his career to improving treatment options for individuals with movement disorders including ataxia, dystonia, essential tremor, Huntington disease, multiple system atrophy, progressive supranuclear palsy, tardive dyskinesia, tics and Tourette syndrome, Lewy body dementia and Parkinson disease. This includes use of botulinum toxin injections and deep brain stimulation to treat movement disorders.

He has maintained an adjunct position with the University of Utah for clinical trials. His primary practice is now located at the Cleo Roberts Clinic in Sun City, Arizona.

Education History

Undergraduate Cornell University College of Arts and Sciences
 BS
Professional Medical Lake Erie College of Osteopathic Medicine
 DO
Internship University of Utah School of Medicine
 Intern
Residency University of Utah School of Medicine
 Resident
Fellowship University of Rochester
 Fellow
Graduate Training University of Rochester
 MS

Selected Publications

Journal Article

  1. Shprecher DR, Flanigan KM, Smith AG, Smith SM, Schenkenberg T, Steffens (2008). Clinical and diagnostic features of delayed hypoxic leukoencephalopathy. The Journal of neuropsychiatry and clinical neurosciences, 20(4), 473-7.
  2. Shprecher D, Schrock L, Himle (2014). Neurobehavioral aspects, pathophysiology, and management of Tourette's syndrome. Current opinion in neurology, 27(4), 484-92.
  3. Fernandez HH, Stamler D, Davis MD, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, Woods SW, Bega D, LeDoux MS, Shprecher DR, Anderson K (2019). Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia. Journal of neurology, neurosurgery, and psychiatry, 90(12), 1317-1323.
  4. Fernandez HH, Stamler D, Davis MD, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, Woods SW, Bega D, LeDoux MS, Shprecher DR, Anderson K (2019). Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia. Journal of neurology, neurosurgery, and psychiatry, 90(12), 1317-1323.
  5. Adler CH, Beach TG, Zhang N, Shill HA, Driver-Dunckley E, Caviness JN, Mehta SH, Sabbagh MN, Serrano GE, Sue LI, Belden CM, Powell J, Jacobson SA, Zamrini E, Shprecher D, Davis KJ, Dugger BN, Hentz J (2019). Unified Staging System for Lewy Body Disorders: Clinicopathologic Correlations and Comparison to Braak Staging. Journal of neuropathology and experimental neurology, 78(10), 891-899.
  6. Huntington Study Group., Frank S, Testa CM, Stamler D, Kayson E, Davis C, Edmondson MC, Kinel S, Leavitt B, Oakes D, O'Neill C, Vaughan C, Goldstein J, Herzog M, Snively V, Whaley J, Wong C, Suter G, Jankovic J, Jimenez-Shahed J, Hunter C, Claassen DO, Roman OC, Sung V, Smith J, Janicki S, Clouse R, Saint-Hilaire M, Hohler A, Turpin D, James RC, Rodriguez R, Rizer K, Anderson KE, Heller H, Carlson A, Criswell S, Racette BA, Revilla FJ, Nucifora F Jr, Margolis RL, Ong M, Mendis T, Mendis N, Singer C, Quesada M, Paulsen JS, Brashers-Krug T, Miller A, Kerr J, Dubinsky RM, Gray C, Factor SA, Sperin E, Molho E, Eglow M, Evans S, Kumar R, Reeves C, Samii A, Chouinard S, Beland M, Scott BL, Hickey PT, Esmail S, Fung WL, Gibbons C, Qi L, Colcher A, Hackmyer C, McGarry A, Klos K, Gudesblatt M, Fafard L, Graffitti L, Schneider DP, Dhall R, Wojcieszek JM, LaFaver K, Duker A, Neefus E, Wilson-Perez H, Shprecher D, Wall P, Blindauer KA, Wheeler L, Boyd JT, Houston E, Farbman ES, Agarwal P, Eberly SW, Watts A, Tariot PN, Feigin A, Evans S, Beck C, Orme C, Edicola J, Christopher (2016). Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial. JAMA, 316(1), 40-50.
  7. Parkinson Study Group SURE-PD3 Investigators (2021). Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. JAMA, 326(10), 926-939.
  8. Shprecher D, Kurlan (2009). The management of tics. Movement disorders, 24(1), 15-24.
  9. Dorsey ER, Voss TS, Shprecher DR, Deuel LM, Beck CA, Gardiner IF, Coles MA, Burns RS, Marshall FJ, Biglan K (2010). A U.S. survey of patients with Parkinson's disease: satisfaction with medical care and support groups. Movement disorders, 25(13), 2128-35.
  10. Litvan I, Lees PS, Cunningham CR, Rai SN, Cambon AC, Standaert DG, Marras C, Juncos J, Riley D, Reich S, Hall D, Kluger B, Bordelon Y, Shprecher DR, for ENGENE-PSP (2016). Environmental and occupational risk factors for progressive supranuclear palsy: Case-control study. Movement disorders, 31(5), 644-52.
  11. Brody DM, Litvan I, Warner S, Riley DE, Hall DA, Kluger BM, Shprecher DR, Cunningham C (2016). Relationship between uric acid levels and progressive supranuclear palsy. Movement disorders, 31(5), 663-7.
  12. Gerstenecker A, Roberson ED, Schellenberg GD, Standaert DG, Shprecher DR, Kluger BM, Litvan (2017). Genetic influences on cognition in progressive supranuclear palsy. Movement disorders, 32(12), 1764-1771.
  13. Park HK, Ilango S, Charriez CM, Checkoway H, Riley D, Standaert DG, Bordelon Y, Shprecher DR, Reich SG, Hall D, Kluger B, Marras C, Jankovic J, Dubinsky R, Litvan I, ENGENE-PSP Study (2018). Lifetime exposure to estrogen and progressive supranuclear palsy: Environmental and Genetic PSP study. Movement disorders, 33(3), 468-472.
  14. Bayram E, Marras C, Standaert DG, Kluger BM, Bordelon YM, Shprecher DR, Litvan I, ENGENE-PSP Consortium (2020). Progressive Supranuclear Palsy and Statin Use. Movement disorders, 35(7), 1253-1257.
  15. Fernandez HH, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, Meltzer HY, Woods SW, Bega D, LeDoux MS, Shprecher DR, Davis C, Davis MD, Stamler D, Anderson K (2017). Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study. Neurology, 88(21), 2003-2010.
  16. Kious BM, Jimenez-Shahed J, Shprecher D (2016). Treatment-refractory Tourette Syndrome. Progress in neuro-psychopharmacology & biological psychiatry, 70, 227-36.
  17. Duff K, Shprecher D, Litvan I, Gerstenecker A, Mast B on behalf of the ENGENE investigator (2013). Correcting for demographic variables on the modified Telephone Interview for Cognitive Status. The American journal of geriatric psychiatry,
  18. Bluett B, Litvan I, Cheng S, Juncos J, Riley DE, Standaert DG, Reich SG, Hall DA, Kluger B, Shprecher D, Marras C, Jankovic J, ENGENE PSP study (2017). Understanding falls in progressive supranuclear palsy. Parkinsonism & related disorders, 35, 75-81.
  19. Marras C, Cunningham CR, Hou J, Proudfoot J, Standaert DG, Juncos J, Riley D, Reich SG, Hall D, Kluger B, Bordelon Y, Shprecher DR, Litvan I, for ENGENE-PSP (2018). Anti-inflammatory drug use and progressive supranuclear palsy. Parkinsonism & related disorders, 48, 89-92.
  20. Rabadia SV, Litvan I, Juncos J, Bordelon Y, Riley DE, Standaert D, Reich SG, Hall DA, Kluger B, Shprecher D, Marras C, Jankovic (2019). Hypertension and progressive supranuclear palsy. Parkinsonism & related disorders, 66, 166-170.
  21. Shoeibi A, Litvan I, Juncos JL, Bordelon Y, Riley D, Standaert D, Reich SG, Shprecher D, Hall D, Marras C, Kluger B, Olfati N, Jankovic (2019). Are the International Parkinson disease and Movement Disorder Society progressive supranuclear palsy (IPMDS-PSP) diagnostic criteria accurate enough to differentiate common PSP phenotypes?. Parkinsonism & related disorders, 69, 34-39.
  22. Rezvanian S, Litvan I, Standaert D, Jankovic J, Reich SG, Hall D, Shprecher DR, Bordelon Y, Dubinsky R, Kluger (2020). Understanding the relationship between freezing of gait and other progressive supranuclear palsy features. Parkinsonism & related disorders, 78, 56-60.
  23. Shprecher D, Noyes Katia, Biglan Kevin, Wang Dongwen, Dorsey Ray E, Kurlan Roger, Adams Michael Jaco (2012). Willingness of Parkinson Disease Patients to Participate in Research Using Internet Based Technology. Telemedicine journal and e-health,
  24. Shprecher D, Mehta (2010). The syndrome of delayed post-hypoxic leukoencephalopathy. NeuroRehabilitation, 26(1), 65-72.
  25. Shprecher D, Schwalb J, Kurlan (2008). Normal pressure hydrocephalus: diagnosis and treatment. Current neurology and neuroscience reports, 8(5), 371-6.
  26. Reilmann R, McGarry A, Grachev ID, Savola JM, Borowsky B, Eyal E, Gross N,Langbehn D, Schubert R, Wickenberg AT, Papapetropoulos S, Hayden M, Squitieri F, Kieburtz K, Landwehrmeyer GB, European Huntington's Disease Network, HuntingtonStudy Group investigators (2018). Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. The Lancet. Neurology,
  27. Mata IF, Jang Y, Kim CH, Hanna DS, Dorschner MO, Samii A, Agarwal P, Roberts JW, Klepitskaya O, Shprecher DR, Chung KA, Factor SA, Espay AJ, Revilla FJ, Higgins DS, Litvan I, Leverenz JB, Yearout D, Inca-Martinez M, Martinez E, Thompson TR, Cholerton BA, Hu SC, Edwards KL, Kim KS, Zabetian C (2015). The RAB39B p.G192R mutation causes X-linked dominant Parkinson's disease. Molecular neurodegeneration, 10, 50.
  28. Beach TG, Adler CH, Zhang N, Serrano GE, Sue LI, Driver-Dunckley E, Mehta SH, Zamrini EE, Sabbagh MN, Shill HA, Belden CM, Shprecher DR, Caselli RJ, Reiman EM, Davis KJ, Long KE, Nicholson LR, Intorcia AJ, Glass MJ, Walker JE, Callan MM, Oliver JC, Arce R, Gerkin R (2020). Severe hyposmia distinguishes neuropathologically confirmed dementia with Lewy bodies from Alzheimer's disease dementia. PloS one, 15(4), e0231720.
  29. Malek-Ahmadi M, Beach TG, Zamrini E, Adler CH, Sabbagh MN, Shill HA, Jacobson SA, Belden CM, Caselli RJ, Woodruff BK, Rapscak SZ, Ahern GL, Shi J, Caviness JN, Driver-Dunckley E, Mehta SH, Shprecher DR, Spann BM, Tariot P, Davis KJ, Long KE, Nicholson LR, Intorcia A, Glass MJ, Walker JE, Callan M, Curry J, Cutler B, Oliver J, Arce R, Walker DG, Lue LF, Serrano GE, Sue LI, Chen K, Reiman E (2019). Faster cognitive decline in dementia due to Alzheimer disease with clinically undiagnosed Lewy body disease. PloS one, 14(6), e0217566.
  30. Barrell K, Bureau B, Turcano P, Phillips GD, Anderson JS, Malik A, Shprecher D, Zorn M, Zamrini E, Savica (2018). High-Order Visual Processing, Visual Symptoms, and Visual Hallucinations: A Possible Symptomatic Progression of Parkinson's Disease. Frontiers in neurology, 9, 999.
  31. Litvan I, Proudfoot JA, Martin ER, Standaert D, Riley D, Hall D, Marras C, Bayram E, Dubinsky RM, Bordelon Y, Reich S, Shprecher D, Kluger B, Cunningham C, Schellenberg GD, Jankovic (2021). Gene-Environment Interactions in Progressive Supranuclear Palsy. Frontiers in neurology, 12, 664796.
  32. Jankovic J, Jimenez-Shahed J, Budman C, Coffey B, Murphy T, Shprecher D, Stamler (2016). Deutetrabenazine in tics associated with Tourette syndrome. Tremor and other hyperkinetic movements (New York, N.Y.), 6,
  33. Shprecher D, Rubenstein L, Gannon K, Frank S, Kurlan (2014). Temporal Course of the Tourette Syndrome Clinical Triad. Tremor and other hyperkinetic movements (New York, N.Y.),
  34. Shprecher D, Gannon K, Agarwal N, Shi X, Anderson (2014). Elucidating the mechanism of tic improvement in Tourette syndrome: a pilot study. Tremor and other hyperkinetic movements (New York, N.Y.),
  35. Adler CH, Beach TG, Zhang N, Shill HA, Driver-Dunckley E, Mehta SH, Atri A, Caviness JN, Serrano G, Shprecher DR, Sue LI, Belden C (2021). Clinical Diagnostic Accuracy of Early/Advanced Parkinson Disease: An Updated Clinicopathologic Study. Neurology. Clinical practice, 11(4), e414-e421.
  36. Shprecher D, Zhang N, Halverson M, Savica (2019). Parkinsonism Risk Factors in Salt Lake City, Utah: A Community-Based Study. Brain sciences, 9(3),
  37. Serrano GE, Shprecher D, Callan M, Cutler B, Glass M, Zhang N, Walker J, Intorcia A, Adler CH, Shill HA, Driver-Dunckley E, Mehta SH, Belden CM, Zamrini E, Sue LI, Vargas D, Beach T (2020). Cardiac sympathetic denervation and synucleinopathy in Alzheimer's disease with brain Lewy body disease. Brain communications, 2(1), fcaa004.
  38. Ganos C, Sarva H, Kurvits L, Gilbert DL, Hartmann A, Worbe Y, Mir P, Müller-Vahl KR, Münchau A, Shprecher D, Singer HS, Deeb W, Okun MS, Malaty IA, Hallett M, Tijssen MA, Pringsheim T, Martino D, Tic Disorders and Tourette Syndrome Study Group of the International Parkinson and Movement Disorder Society (2021). Clinical Practice Patterns in Tic Disorders Among Movement Disorder Society Members. Tremor and other hyperkinetic movements (New York, N.Y.), 11, 43.
  39. Martino D, Malaty I, Müller-Vahl K, Nosratmirshekarlou E, Pringsheim TM, Shprecher D, Ganos C, Movement Disorders Society Tourette Syndrome Study Group (2021). Treatment failure in persistent tic disorders: an expert clinicians' consensus-based definition. European child & adolescent psychiatry,
  40. Serrano GE, Walker JE, Tremblay C, Piras IS, Huentelman MJ, Belden CM, Goldfarb D, Shprecher D, Atri A, Adler CH, Shill HA, Driver-Dunckley E, Mehta SH, Caselli R, Woodruff BK, Haarer CF, Ruhlen T, Torres M, Nguyen S, Schmitt D, Rapscak SZ, Bime C, Peters JL, Alevritis E, Arce RA, Glass MJ, Vargas D, Sue LI, Intorcia AJ, Nelson CM, Oliver J, Russell A, Suszczewicz KE, Borja CI, Cline MP, Hemmingsen SJ, Qiji S, Hobgood HM, Mizgerd JP, Sahoo MK, Zhang H, Solis D, Montine TJ, Berry GJ, Reiman EM, Röltgen K, Boyd SD, Pinsky BA, Zehnder JL, Talbot P, Desforges M, DeTure M, Dickson DW, Beach T (2022). SARS-CoV-2 Brain Regional Detection, Histopathology, Gene Expression, and Immunomodulatory Changes in Decedents with COVID-19. Journal of neuropathology and experimental neurology,
  41. Elliott JE, Lim MM, Keil AT, Postuma RB, Pelletier A, Gagnon JF, St Louis EK, Forsberg LK, Fields JA, Huddleston DE, Bliwise DL, Avidan AY, Howell MJ, Schenck CH, McLeland J, Criswell SR, Videnovic A, During EH, Miglis MG, Shprecher DR, Lee-Iannotti JK, Boeve BF, Ju YS, North American Prodromal Synucleinopathy (NAPS) Consortiu (2023). Baseline characteristics of the North American prodromal Synucleinopathy cohort. Annals of clinical and translational neurology,
  42. Camilleri M, Subramanian T, Pagan F, Isaacson S, Gil R, Hauser RA, Feldman M, Goldstein M, Kumar R, Truong D, Chhabria N, Walter BL, Eskenazi J, Riesenberg R, Burdick D, Tse W, Molho E, Robottom B, Bhatia P, Kadimi S, Klos K, Shprecher D, Marquez-Mendoza O, Hidalgo G, Grill S, Li G, Mandell H, Hughes M, Stephenson S, Vandersluis J, Pfeffer M, Duker A, Shivkumar V, Kinney W, MacDougall J, Zasloff M, Barbut (2022). Oral ENT-01 Targets Enteric Neurons to Treat Constipation in Parkinson Disease : A Randomized Controlled Trial. Annals of internal medicine, 175(12), 1666-1674.
  43. Levendowski DJ, Walsh CM, Boeve BF, Tsuang D, Hamilton JM, Salat D, Berka C, Lee-Iannotti JK, Shprecher D, Westbrook PR, Mazeika G, Yack L, Payne S, Timm PC, Neylan TC, St Louis E (2022). Non-REM sleep with hypertonia in Parkinsonian Spectrum Disorders: A pilot investigation. Sleep medicine, 100, 501-510.
  44. Adler CH, Halverson M, Zhang N, Shill HA, Driver-Dunckley E, Mehta SH, Atri A, Caviness JN, Serrano GE, Shprecher DR, Belden CM, Sabbagh MN, Long K, Beach T (2024). Conjugal Synucleinopathies: A Clinicopathologic Study. Movement disorders,
  45. Choudhury P, Lee-Iannotti JK, Busicescu AO, Rangan P, Fantini ML, Avidan AY, Bliwise DL, Criswell SR, During EH, Elliott JE, Fields JA, Gagnon JF, Howell MJ, Huddleston DE, McLeland J, Mignot E, Miglis MG, Lim MM, Pelletier A, Schenck CH, Shprecher D, St Louis EK, Videnovic A, Ju YS, Boeve BF, Postuma R, as the NAPS Consortiu (2024). Validation of the RBD Symptom Severity Scale in the North American Prodromal Synucleinopathy Consortium. Neurology, 102(3), e208008.
  46. Elliott JE, Ligman BR, Bryant-Ekstrand MD, Keil AT, Powers K, Olivo C, Neilson L, Postuma RB, Pelletier A, Gagnon JF, Gan-Or Z, Yu E, Liu L, St Louis EK, Forsberg LK, Fields JA, Ross OA, Huddleston DE, Bliwise DL, Avidan AY, Howell MJ, Schenck CH, McLeland J, Criswell SR, Videnovic A, During EH, Miglis MG, Shprecher DR, Lee-Iannotti JK, Boeve BF, Ju YS, Lim MM, North American Prodromal Synucleinopathy (NAPS) Consortium (2024). Comorbid neurotrauma increases neurodegenerative-relevant cognitive, motor, and autonomic dysfunction in patients with REM sleep behavior disorder: A substudy of the North American Prodromal Synucleinopathy Consortium. Sleep,
  47. McGarry A, Rosanbalm S, Leinonen M, Olanow CW, To D, Bell A, Lee D, Chang J, Dubow J, Dhall R, Burdick D, Parashos S, Feuerstein J, Quinn J, Pahwa R, Afshari M, Ramirez-Zamora A, Chou K, Tarakad A, Luca C, Klos K, Bordelon Y, St Hiliare MH, Shprecher D, Lee S, Dawson TM, Roschke V, Kieburtz (2024). Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial. The Lancet. Neurology, 23(1), 37-45.
  48. Hamedani AG, Auinger P, Willis AW, Safarpour D, Shprecher D, Stover N, Subramanian T, Cloud (2023). Adjusting for Underrepresentation Reveals Widespread Underestimation of Parkinson's Disease Symptom Burden. Movement disorders, 38(9), 1679-1687.

Review

  1. Lyon G, Shprecher D, Coffey B, Kurlan (2010). Tourette's Disorder. Current treatment options in neurology, 12(4), 274-286.

Case Report

  1. Shprecher D, Grossmann K, Tward (2014). Sustained remission of Parkinson disease associated melanoma with immunotherapy. Parkinsonism & related disorders,

Editorial

  1. Shprecher DR, Majersik J (2017). The virtual house call: A 21st-century innovation in the care of patients with Parkinson disease. Neurology, 89(11), 1103-1104.